Clarithromycin is a new macrolide antibiotic which is active against Gram-positive and Gram negative bacteria. Community acquired pneumonia is mostly caused by Gram-positive bacilli. The effectiveness of twice daily 250 mg clarithomycin in the treatment of hospitalized patients with community acquired pneumonia was studied. This study is an open clinical trial without control. Subjects were 30 …